Scientists Find a Blood Signal That May Reveal Ovarian Cancer Before It Turns Invasive

A new blood signal flagged a hidden precursor to the deadliest ovarian cancer in 92% of women who had it. Here's what it could mean for Black women.

By EEW Magazine Online Editors

A laboratory scientist examines a blood sample. Researchers at Hoag Family Cancer Institute report that an experimental blood test detected a microscopic precursor to the deadliest form of ovarian cancer in an early study. (Real People Group/Getty Images)

Ovarian cancer can begin with changes so small that a woman feels nothing, an ultrasound shows nothing and routine blood work raises no alarm. Those changes often take root in the lining of the fallopian tubes, and by the time the disease is diagnosed, it has frequently spread beyond the ovaries. That silent start has long made ovarian cancer one of the deadliest cancers women face.

Now scientists in California have identified a molecular signal in the blood that may reveal those changes before invasive cancer develops.

In a study published Nov. 10 in Nature Medicine, researchers at Hoag Family Cancer Institute in Newport Beach reported that an experimental blood test detected a microscopic precancerous lesion linked to ovarian cancer in 92.3% of women who had it in a validation group. The test also correctly identified 98.2% of healthy women.

The eight-year study, which brought together scientists and blood samples from several countries, is an early step toward detecting a disease that has no effective routine screening test. Researchers caution that larger clinical studies are needed before the test can be offered to patients.

"Ovarian cancer does not begin the day we discover a tumor," study leader Dr. Rajan Gogna, director of translational research at the Hoag Family Cancer Institute, said in a statement. His team set out to learn whether a warning could appear in the blood before a tumor ever forms.

The signal they found is an RNA molecule called Tu-Stroma, which travels through the bloodstream inside microscopic particles.

The research focused on high-grade serous ovarian cancer, the deadliest form of the disease, which often begins in the fallopian tubes as tiny lesions called serous tubal intraepithelial carcinoma, or STIC. These lesions are too small to appear on imaging and are usually found only when tissue removed during surgery is examined under a microscope.

High-grade serous ovarian cancer, the deadliest form of the disease, often begins in the fallopian tubes, where precancerous lesions are too small to see on imaging.

The team analyzed blood from 506 people, including 43 with isolated STIC lesions. Tu-Stroma levels were elevated in women with STIC and in women with early-stage cancer. The marker also separated women with STIC from healthy women far better than CA-125, the blood test doctors commonly use to monitor ovarian cancer.

The American Cancer Society estimates that about 21,010 women in the United States will be diagnosed with ovarian cancer in 2026 and about 12,450 will die from it.

Ovarian cancer is diagnosed more often in white women, yet Black women are less likely to survive it. Between 1975 and 2016, the National Cancer Institute reports, five-year relative survival rose from 33% to 48% among white women and fell from 44% to 41% among Black women.

Researchers have not yet shown how well Tu-Stroma performs across racially diverse populations or whether using it would save lives. Those answers will help determine whether the discovery can narrow that survival gap.

The finding could matter most for women with inherited mutations such as BRCA1 and BRCA2. Many are advised to have their fallopian tubes and ovaries removed to lower their risk. The surgery sharply reduces the chance of ovarian cancer, but removing the ovaries before natural menopause brings on menopause immediately and ends natural fertility.

Those decisions now rest on genetic risk, family history and clinical guidelines. Doctors have no way to know beforehand whether precancerous lesions are already present.

"For women at high risk, this could transform how we approach prevention," said Dr. Esha Madan, who co-led the research at Hoag. Her team is also studying ways to stop the lesions from progressing, work that could one day spare some women preventive surgery.

For now, the test remains experimental. The study examined stored blood from women whose diagnoses were already known, a design that can make a test look more accurate than it would be in everyday use. Only 43 participants had isolated STIC, and the test has not yet been tried in women followed over time.

Hoag estimates that in a high-risk population, about 72% of positive results would be accurate. That means roughly one in four positive results could be a false alarm.

Gogna has also cautioned against reading too much into a clean result. "A negative result cannot currently exclude STIC or justify delaying recommended preventive surgery," he told Inside Precision Medicine.

Hoag plans studies that will collect blood from women with and without elevated genetic risk and follow them over time. Researchers want to learn how early the signal appears, how reliably it identifies precancerous disease and whether it can safely guide medical decisions.

Until then, knowing the warning signs remains a woman's best defense. The Centers for Disease Control and Prevention lists several warning signs: unusual vaginal bleeding or discharge, pelvic pain or pressure, abdominal or back pain, bloating, feeling full too quickly, and changes in bathroom habits such as frequent or urgent urination or constipation.

The CDC advises women with unusual vaginal bleeding to see a doctor right away. Any other symptom that lasts two weeks or longer and is unusual for a woman should also be checked. Many of these symptoms have other causes, which is one reason ovarian cancer is so often missed.

The U.S. Preventive Services Task Force recommends against routine ovarian cancer screening for women without symptoms who are not known to have a high-risk hereditary cancer syndrome. Existing screening methods have not been shown to reduce deaths and can lead to unnecessary surgery. Women with a strong family history of ovarian or breast cancer should ask their doctors about genetic counseling and testing.

If larger studies confirm what Hoag's researchers found, women at the highest risk could one day face one of the hardest decisions of their lives with something they have never had: biological evidence of what is happening inside their bodies before cancer takes hold.

Previous
Previous

Heavy Periods, Constant Fatigue and the Low Iron a Routine Blood Test Can Miss

Next
Next

As Black Mothers Face Higher Childbirth Risks, an HBCU Is Training Doulas to Stand With Them